Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen: Determination of I-123 Radiation Dosimetry for 123-I-MIP-1072 and 123-I-MIP-1095

NCT00712829 is registered in ClinicalTrials.gov with Molecular Insight Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00712829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00712829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen: Determination of I-123 Radiation Dosimetry for 123-I-MIP-1072 and 123-I-MIP-1095
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2008
Completion date
January 31, 2009
Enrollment
12 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer